Hormonal Coc Spiro denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for hormonal coc spiro are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Deny a Combined COC + Spironolactone Regimen as Experimental

An "experimental or investigational" denial means Cigna has determined the specific use of a combined oral contraceptive (COC) with spironolactone lacks sufficient evidence to meet its coverage criteria for the requested indication. This framing is common for off-label uses — situations where the combination is widely used in clinical practice but the FDA-approved labeling for one or both agents does not explicitly cover the precise indication being treated.

These denials are frequently overturned on appeal. Major specialty societies in dermatology, endocrinology, and gynecology have published clinical practice guidelines supporting dual therapy for conditions such as PCOS-related hyperandrogenism, acne, and hirsutism. Guidelines from recognized professional organizations constitute peer-reviewed evidence that directly counters an "experimental" characterization.

## Your Federal Appeal Rights

ACA Section 2719 requires non-grandfathered plans to offer internal appeal and independent external review. ERISA Section 503 applies to employer-sponsored plans. The external review window is generally approximately four months from the date of a final internal denial. An expedited review is available when your health condition does not permit a standard timeline.

## Appeal Process and Timeline

1. Obtain the full denial letter, including the specific evidentiary standard Cigna applied. 2. File a written internal appeal by the deadline on your EOB (commonly 180 days). 3. Request external review from Cigna's designated IRO if the internal appeal is upheld. 4. Ask your prescriber to submit a peer-to-peer review request with Cigna's medical director — this step resolves many experimental denials before formal appeal.

## Documentation to Gather

• Diagnosis records: Chart documentation of the specific condition, its severity, and laboratory findings.
• Prescriber's medical-necessity letter: Should specifically address why the combination is supported by current evidence and cite the applicable guideline organization (without relying solely on off-label marketing).
• Published clinical guidelines: Copies of the relevant society guideline recommending or supporting the combination for this indication.
• Prior treatment history: Documentation of treatments already tried, with dates and outcomes, showing this is not a first-line experiment.

## Criteria-Mapping Structure

Review Cigna's coverage policy for the definition of "experimental" it applies. Then map your evidence to each element:

| Cigna's Experimental Criteria Element | Your Rebuttal Evidence | |---|---| | No peer-reviewed clinical evidence | Applicable specialty society guideline (cite organization, not numbers) | | Not FDA-approved for this indication | Prescriber letter explaining established clinical practice and off-label evidence | | No consensus in the medical community | Multiple guidelines from distinct professional organizations |

Confirm with your prescriber that the specific use is consistent with the FDA-approved prescribing label to the extent applicable, and obtain their written attestation that this reflects accepted standard of care.